On Tuesday, Shares of Kinder Morgan, Inc. (NYSE:KMI), lost -0.27% to $33.66.
A partner of Kinder Morgan declared the start of a binding open season to solicit interest for incremental firm natural gas transportation service on its Mier-Monterrey pipeline, which would expand capacity to about 1.340 billion cubic feet per day. The expansion project, which would be accomplished by the fourth quarter of 2017, will comprise of the looping of the existing Mier-Monterrey pipeline system from the Mexico-United States border to Huinalá, Nuevo León, Mexico, and a new lateral from Pesquería, Nuevo León, Mexico, to Escobedo, Nuevo León, Mexico.
The open season bid period starts on Aug. 13, 2015, and ends at 5 p.m. Central Time on Aug. 22, 2015.
Kinder Morgan, Inc. operates as an energy infrastructure and energy company in North America. The company operates through Natural Gas Pipelines, CO2, Terminals, Products Pipelines, Kinder Morgan Canada, and Other segments.
Shares of Mallinckrodt public limited company (NYSE:MNK), declined -14.07% to $106.73, during its last trading session.
Mallinckrodt public limited company stated results for the third quarter of fiscal 2015, which ended June 26, 2015.
Net sales were $965.1 million contrast with $653.1 million in the third quarter of fiscal 2014, an enhance of 47.8%. The enhance was primarily driven by the inclusion in the company’s portfolio of H.P. Acthar® Gel (repository corticotropin injection) and INOMAX® (nitric oxide) for inhalation, attained in August 2014 and April 2015, respectively, and higher net sales of hydrocodone-related products within the Specialty Generics segment. The enhance was partially offset by reduced net sales of methylphenidate HCl extended-release (ER) tablets, USP, CII and oxycodone-related products within the Specialty Generics segment, and net sales within the Global Medical Imaging segment. In addition, the negative impact of foreign currency lowered stated net sales by $24.8 million, driven primarily by changes in the Euro.
Mallinckrodt public limited company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging.
Finally, Vishay Intertechnology Inc. (NYSE:VSH), ended its last trade with -4.43% loss, and closed at $10.79, hitting its lowest level.
Vishay Intertechnology declared its results for the fiscal quarter and six fiscal months ended July 4, 2015.
Revenues for the fiscal quarter ended July 4, 2015 were $590.5 million, contrast to $641.9 million for the fiscal quarter ended June 28, 2014. The net earnings attributable to Vishay stockholders for the fiscal quarter ended July 4, 2015 were $26.3 million, or $0.17 per diluted share, contrast to $35.6 million, or $0.23 per diluted share for the fiscal quarter ended June 28, 2014.
Net earnings attributable to Vishay stockholders for the fiscal quarter ended July 4, 2015 comprises restructuring and severance costs of $5.7 million. Net earnings attributable to Vishay stockholders for the fiscal quarter ended June 28, 2014 comprises restructuring and severance costs of $9.0 million. These items are summarized on the attached reconciliation plan. Adjusted earnings per diluted share, which exclude these items, were $0.20 and $0.27 for the fiscal quarters ended July 4, 2015 and June 28, 2014, respectively.
Vishay Intertechnology, Inc. manufactures and supplies discrete semiconductors and passive components in the United States, Europe, and Asia. The company operates in five segments: MOSFETs, Diodes, Optoelectronic Components, Resistors & Inductors, and Capacitors.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
